Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
I read post #14 twice before replying, because I had assumed the opposite.
Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.
On post #19 — agreed on the reasoning, with one qualification.
The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.
Picking up post #45: that is the part I would want checked first.
Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
Worth separating two things that post #72 runs together.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
I read post #104 twice before replying, because I had assumed the opposite.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Read the full topic (106 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1
On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…
|
+27 | 31 | 671 | 12mo |
|
Amylin and gastric emptying: overlapping mechanisms with incretins
On the subject in the title: Amylin and gastric emptying: overlapping mechanisms with incretins Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…
|
2 | 50k | 17mo | |
|
Cagrilintide molecular characteristics and analytical considerations
Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of a claim I…
|
4 | 41k | 12mo | |
|
Reading a combination trial: attributing effect to components
On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
|
4 | 19k | 11mo | |
|
Follow-up: Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…
|
2 | 41k | 14mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…
|
+149 | 159 | 30k | 15mo |
|
Coming back to: Measurement error in a self-reported exposure
Measurement error in a self-reported exposure — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
|
+23 | 27 | 49k | 3mo |
|
Coming back to: A critique that turned out to be unfair, retracted by its author
A critique that turned out to be unfair, retracted by its author — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not…
|
2 | 1.3k | 14mo | |
|
Journal club: SUSTAIN 6 and its retinopathy signal
On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I do not think it…
|
+110 | 122 | 46k | 1d |
|
Open-label extensions: what survives and what does not
Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with PIONEER 6 ( N Engl J Med ,…
|
4 | 22k | 3mo |